Astellas Acquires Mitobridge Under Existing Collaboration

Astellas Acquires Mitobridge Under Existing Collaboration

Firm News

On November 30, 2017, Astellas Pharma Inc. and Mitobridge, Inc. announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing an R&D collaboration focused on discovering and developing novel drugs that target mitochondrial function. Mitobridge will become a wholly-owned subsidiary of Astellas following the close of the acquisition.

Rosemary Reilly leads the WilmerHale team representing Mitobridge in this transaction, which also includes Steve Barrett, Bill Caporizzo, Jeff Hermanson, Andrew Langworthy, Benjamin Kelsey and Nils Remole.

Astellas and Mitobridge's full press release can be found on www.mitobridge.com

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.